Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by State Street Corp

State Street Corp lowered its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 216,021 shares of the company's stock after selling 9,876,644 shares during the period. State Street Corp owned approximately 0.39% of Ginkgo Bioworks worth $1,761,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of DNA. AQR Capital Management LLC acquired a new stake in Ginkgo Bioworks in the second quarter worth about $3,391,000. Monaco Asset Management SAM acquired a new stake in Ginkgo Bioworks in the 2nd quarter worth approximately $3,276,000. Renaissance Technologies LLC purchased a new stake in Ginkgo Bioworks during the 2nd quarter worth approximately $2,128,000. XTX Topco Ltd acquired a new position in Ginkgo Bioworks during the 2nd quarter valued at approximately $312,000. Finally, Mackenzie Financial Corp acquired a new position in Ginkgo Bioworks during the 2nd quarter valued at approximately $251,000. Institutional investors own 78.63% of the company's stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen boosted their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $4.58.

Ginkgo Bioworks Price Performance

Shares of DNA traded up $0.40 during trading hours on Thursday, hitting $10.22. The stock had a trading volume of 1,799,711 shares, compared to its average volume of 1,175,440. The business's 50-day moving average is $8.79. The firm has a market cap of $587.44 million, a price-to-earnings ratio of -0.78 and a beta of 1.17. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $66.00.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.